37178-28-2 Usage
General Description
1-(benzyloxy)-3-(3,4-dihydroxyphenyl)-1-oxopropan-2-aminium chloride is a chemical compound that contains a positively charged amino group and a chloride ion. It is derived from benzyloxy and 3,4-dihydroxyphenyl, and has a one-oxo-propan-2-aminium group. 1-(benzyloxy)-3-(3,4-dihydroxyphenyl)-1-oxopropan-2-aminium chloride may have potential applications in pharmaceuticals, as it contains a benzyl group, hydroxyphenyl group, and an oxo group, which are common functional groups found in many bioactive compounds. The presence of the chloride ion also gives the compound potential applications in chemical reactions and synthesis. Overall, this compound has the potential to be used in various chemical and pharmaceutical applications due to its structural features.
Check Digit Verification of cas no
The CAS Registry Mumber 37178-28-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,1,7 and 8 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 37178-28:
(7*3)+(6*7)+(5*1)+(4*7)+(3*8)+(2*2)+(1*8)=132
132 % 10 = 2
So 37178-28-2 is a valid CAS Registry Number.
37178-28-2Relevant articles and documents
Synthesis and polymerization studies of organic-soluble eumelanins
Lawrie, Kirsten J.,Meredith, Paul,McGeary, Ross P.
, p. 632 - 638 (2008)
The isolation, structure determination and chemical characterization of eumelanins has been plagued by their very low solubility in organic solvents. To gain insights into the structure and reactivity of these unusual and important biologic macromolecules
NON-NATURAL AMINO ACID DERIVATIVES
-
Page/Page column 15-16, (2008/06/13)
Compounds of formula (I) have activity in alleviating the effects of impaired dopaminergic signaling, for example in the treatment of Parkinsons Disease; wherein: R1 is a carboxyl, carboxyl ester, or carboxamide group; R2 and R3
Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
-
, (2008/06/13)
There is provided, novel, transient pro-drug forms of L-DOPA (3,4-dihydroxy-L-phenylalanine), having the formula: SPC1 Wherein R represents a member selected from the group consisting of a hydrogen atom, a --COCH3 group, a --COC2 Hs